Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· April 3, 2026
Novo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts
View original at finance.yahoo.comNovo Nordisk Shares Down 43% in a Year as Generic Rivals Force 48% Price Cuts Quick Read Novo Nordisk (NVO) cut Wegovy and Ozempic prices up to 48% in India due to generic semaglutide competition, while shares have fallen 43% over the past year to $36.98 as 2026 guidance signals -5% to -13% adjusted sales growth; the c…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Phase 3 data showed 14.2% weight loss in type 2 diabetes patients for CagriSema
60% confidenceWegovy HD achieved an average weight loss of 20.7% over 72 weeks
60% confidence2026 guidance signals -5% to -13% adjusted sales growth
60% confidenceCagriSema (cagrilintide plus semaglutide) is expected to receive FDA obesity decision around end of 2026/early 2027
60% confidence
Data points we hold from this source
| Novo Nordisk · stock price 52 week low | 35.12 USD |